HESTERBIO - Hester Biosciences Ltd Share Price

Pharmaceuticals & Biotechnology

₹1838.10-74.40(-3.89%)

Market Closed as of Apr 29, 2025, 15:30 IST

What does Hester Biosciences Ltd do?

Pharmaceuticals•Healthcare•Small Cap

Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through Poultry Healthcare, Animal Healthcare, and Petcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers livestock vaccines for goat pox, peste des petits ruminants, brucella abortus, contagious bovine pleuropneumonia, CCPP, and lumpy skin diseases; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, coat nutrition, grooming aids, and anti-infective formulations. Additionally, the company provides seroprofiling kits; diagnostic labs for poultry flocks; and mastitis control programs for cattle; as well as engages in manufacturing and trading of goods. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India.

Industry Group:Pharmaceuticals & Biotechnology

Employees:642

Website:www.hester.in

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Category	HESTERBIO	Pharmaceuticals
PE	48.31	36.86
PS	5.03	5.19
Growth	7 %	7.1 %

Description	Share	Value
Poultry Healthcare	59.7%	37.7 Cr
Animal Healthcare	38.8%	24.5 Cr
PetCare	1.5%	96.8 L
Total		63.2 Cr

Share Holdings

Understand Hester Biosciences ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

As of 2025-03-31

Shareholder Name	Holding %
Rajiv Dinesh Gandhi	10.47%
Sanjiv Dinesh Gandhi	8.2%
Nina Rajiv Gandhi	8.19%
Shaila Bhupendra Gandhi	5.78%
Ravin Gandhi	4.74%
Bela Gandhi	4.71%
Bhupendra Vithaldas Gandhi	4.69%
Kuntal Hasmukhlal Shah	3.17%
Biolink Healthcare Limited	2.93%
Manish Jain	2.88%
Anup Chandravadan Kapadia	2.68%
HUF	2.58%
Darshna Dinesh Kapadia	1.81%
Vinay Shah	1.28%
Manish Prataprai Gandhi	1.18%
Jagrut Prataprai Gandhi	1.18%
Sandeep Shantilal Gala	1.06%
Hester Coatings LLP	0.75%
LLP	0.34%
Hester Diagnostics Private Limited	0.28%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Balance Sheet for Hester Biosciences

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-21.3%	2.11	2.41	1.63	4.3	1.9	1.53
Loans, current	1.5%	5.76	5.69	5.67	5.85	6.09	5.88
Total current financial assets	12.3%	129	115	131	111	98	79
Inventories	-11.8%	61	69	73	79	71	71
Current tax assets	-	0	0	0	-	0	-
Total current assets	3.4%	211	204	225	216	188	166
Property, plant and equipment	3.9%	107	103	104	108	101	84
Capital work-in-progress	1.8%	171	168	162	146	110	80
Non-current investments	48.8%	65	44	65	65	65	65
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	42.6%	68	48	70	69	69	71
Total non-current assets	1.7%	351	345	339	330	304	258
Total assets	2.2%	562	550	564	546	491	424
Borrowings, non-current	-19.2%	64	79	88	83	90	73
Total non-current financial liabilities	-19%	65	80	88	84	91	74
Provisions, non-current	20.6%	2.52	2.26	1.98	1.72	1.41	1.08
Total non-current liabilities	-10.1%	125	139	145	117	122	81
Borrowings, current	37.7%	74	54	74	81	66	49
Total current financial liabilities	15.1%	108	94	114	123	90	72
Provisions, current	-30.3%	0.57	0.67	0.63	0.44	0.34	0.24
Current tax liabilities	15%	2.15	2	2.64	3.39	2.43	0.94
Total current liabilities	14.4%	112	98	120	136	94	75
Total liabilities	0%	237	237	265	253	216	156
Equity share capital	0%	8.51	8.51	8.51	8.51	8.51	8.51
Total equity	3.8%	325	313	299	292	275	268
Total equity and liabilities	2.2%	562	550	564	546	491	424

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	8.3%	14	13	13	13	17	25
Loans, current	-1.4%	5.79	5.86	5.83	5.99	6.09	6.08
Total current financial assets	13.6%	135	119	137	117	109	102
Inventories	-12%	67	76	80	85	77	75
Current tax assets	-	0	-	-	0	0	-
Total current assets	3.3%	222	215	238	228	206	195
Property, plant and equipment	-1.7%	235	239	245	259	255	237
Capital work-in-progress	1.8%	171	168	162	146	110	80
Non-current investments	-	0	0	0	25	23	21
Total non-current financial assets	-9.7%	3.52	3.79	5.06	30	28	27
Total non-current assets	-0.2%	447	448	445	442	418	367
Total assets	1.1%	669	662	683	670	624	562
Borrowings, non-current	-14.9%	155	182	190	185	190	165
Total non-current financial liabilities	-13.8%	164	190	197	191	197	170
Provisions, non-current	20.9%	2.85	2.53	2.26	1.93	1.41	1.27
Total non-current liabilities	-10.3%	228	254	260	233	244	198
Borrowings, current	48.2%	84	57	77	83	71	58
Total current financial liabilities	22.1%	117	96	122	130	104	91
Provisions, current	-33.3%	0.68	0.76	0.66	0.51	0.6	0.28
Current tax liabilities	-2.1%	2.43	2.46	2.69	3.4	2.55	0.94
Total current liabilities	20%	127	106	132	149	109	97
Total liabilities	-1.1%	355	359	391	381	353	295
Equity share capital	0%	8.51	8.51	8.51	8.51	8.51	8.51
Non controlling interest	10%	12	11	9.61	8.82	6.66	7.41
Total equity	3.6%	314	303	292	289	271	267
Total equity and liabilities	1.1%	669	662	683	670	624	562

Cash Flow for Hester Biosciences

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	-26%	4.89	6.26	0
Change in inventories	205.5%	11	-8.48	-13.72
Depreciation	-0.1%	9.78	9.79	9.5
Unrealised forex losses/gains	-21.7%	-0.12	0.08	0.78
Adjustments for interest income	-16.5%	1.91	2.09	1.9
Net Cashflows from Operations	32.5%	54	41	32
Income taxes paid (refund)	41.6%	11	8.06	16
Net Cashflows From Operating Activities	31.2%	43	33	16
Proceeds from sales of PPE	3.1%	0.06	0.03	0.18
Purchase of property, plant and equipment	-70.8%	22	73	91
Interest received	256.1%	1.89	0.43	0.26
Other inflows (outflows) of cash	-57.1%	-0.21	0.23	-20.36
Net Cashflows From Investing Activities	70.4%	-20.63	-71.96	-110.58
Proceeds from borrowings	-62.7%	20	52	118
Repayments of borrowings	206.2%	50	17	13
Dividends paid	-22.8%	6.8	8.51	8.51
Interest paid	35.3%	13	9.87	1.36
Other inflows (outflows) of cash	8.7%	26	24	0
Net Cashflows from Financing Activities	-162.7%	-24.07	41	95
Net change in cash and cash eq.	-263.3%	-1.89	2.77	0.28

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	125.3%	19	8.99	0
Change in inventories	178.9%	9.23	-9.43	-13.16
Depreciation	90.7%	17	9.39	17
Unrealised forex losses/gains	-21.7%	-0.12	0.08	0.78
Adjustments for interest income	-22.2%	1.91	2.17	1.9
Net Cashflows from Operations	90.3%	60	32	26
Income taxes paid (refund)	54.7%	12	8.11	17
Net Cashflows From Operating Activities	104.3%	48	24	8.81
Proceeds from sales of PPE	3.1%	0.06	0.03	0.18
Purchase of property, plant and equipment	-70.1%	24	78	96
Interest received	281.6%	1.89	0.51	0.26
Other inflows (outflows) of cash	-57.1%	-0.21	0.23	-0.51
Net Cashflows From Investing Activities	69.7%	-22.65	-77	-116.59
Payments of other equity instruments	-	0	0	0.41
Proceeds from borrowings	-65.5%	20	56	135
Repayments of borrowings	206.2%	50	17	18
Payments of lease liabilities	-	0.3	0	0
Dividends paid	-22.8%	6.8	8.51	8.51
Interest paid	16.7%	15	13	2.54
Other inflows (outflows) of cash	8.7%	26	24	6.19
Net Cashflows from Financing Activities	-166%	-26.05	42	112
Effect of exchange rate on cash eq.	11.6%	0.16	0.05	-0.35
Net change in cash and cash eq.	88.8%	-0.41	-11.59	3.48

Income Statement for Hester Biosciences

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	12.3%	285	254	219	208	169	171
Other Income	-24.5%	4.26	5.32	4.66	1.65	2.93	3.1
Total Income	11.6%	289	259	224	210	172	174
Cost of Materials	14.3%	33	29	35	24	21	23
Purchases of stock-in-trade	3.7%	57	55	39	25	17	14
Employee Expense	19.1%	57	48	39	33	37	27
Finance costs	-25.6%	5.09	6.5	2.47	3.95	5.03	3.54
Depreciation and Amortization	-0.1%	9.78	9.79	9.5	9.63	9.38	7.57
Other expenses	14.3%	81	71	58	50	57	47
Total Expenses	17.8%	253	215	171	150	131	115
Profit Before exceptional items and Tax	-16.3%	37	44	53	60	41	60
Exceptional items before tax	-	0	0	0	-5.28	0	0
Total profit before tax	-16.3%	37	44	53	55	41	60
Current tax	-13.7%	9.63	11	14	16	12	15
Deferred tax	-657.1%	-0.06	0.86	-0.51	-1.48	-1.8	0.66
Total tax	-22.1%	9.57	12	14	15	10	16
Total profit (loss) for period	-16.1%	27	32	40	40	31	44
Other comp. income net of taxes	-14.6%	-0.02	0.11	-0.16	0.21	-0.4	-0.24
Total Comprehensive Income	-16.1%	27	32	39	40	31	44
Earnings Per Share, Basic	-16.4%	31.93	38.018	46.45	46.9	36.7	35.92
Earnings Per Share, Diluted	-16.4%	31.93	38.018	46.45	46.9	36.7	35.92

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	-15.1%	63	74	73	73	66	66
Other Income	-14.3%	1.3	1.35	1.06	1.2	0.98	1.22
Total Income	-14.9%	64	75	75	74	66	68
Cost of Materials	-25.6%	8.44	11	11	9.17	6.65	8.43
Purchases of stock-in-trade	33.2%	12	9.26	9.93	14	14	12
Employee Expense	0%	14	14	14	14	14	15
Finance costs	47.5%	1.59	1.4	1.13	1.31	1.37	1.48
Depreciation and Amortization	4.2%	2.24	2.19	2.12	2.08	2.57	2.58
Other expenses	-5.3%	19	20	23	23	19	19
Total Expenses	-6.6%	58	62	63	64	58	58
Profit Before exceptional items and Tax	-50.1%	6.49	12	11	10	8.61	9.16
Total profit before tax	-50.1%	6.49	12	11	10	8.61	9.16
Current tax	-68.1%	1.66	3.07	2.87	3.28	1.51	2.48
Deferred tax	33.7%	0.39	0.08	0	-0.48	0.63	-0.11
Total tax	-50.9%	2.05	3.14	2.87	2.79	2.14	2.38
Total profit (loss) for period	-58.8%	4.44	9.34	8.43	7.43	6.47	6.78
Other comp. income net of taxes	0%	-0.01	-0.01	-0.01	-0.11	0.03	0.03
Total Comprehensive Income	-58.8%	4.43	9.33	8.43	7.32	6.5	6.81
Earnings Per Share, Basic	-57.7%	5.22	10.97	9.91	8.74	7.61	7.97
Earnings Per Share, Diluted	-57.7%	5.22	10.97	9.91	8.74	7.61	7.97

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	14.7%	305	266	235	214	183	178
Other Income	-28.6%	11	15	14	4.68	6.37	7.21
Total Income	12.1%	315	281	249	219	190	185
Cost of Materials	1.9%	54	53	61	39	29	29
Purchases of stock-in-trade	10.3%	33	30	13	7.97	6.52	7.13
Employee Expense	14.5%	64	56	45	39	41	29
Finance costs	128.4%	20	9.32	4.06	6.6	7.37	6.63
Depreciation and Amortization	-20%	17	21	17	13	13	12
Other expenses	11.1%	91	82	67	57	68	52
Total Expenses	17.1%	288	246	196	166	148	128
Profit Before exceptional items and Tax	-25.7%	27	36	53	53	41	57
Exceptional items before tax	-	0	0	0	-3.32	0	0
Total profit before tax	-25.7%	27	36	53	50	41	57
Current tax	0%	11	11	15	17	12	15
Deferred tax	-487.5%	0.06	0.84	-0.77	-1.54	-1.84	0.74
Total tax	-9.1%	11	12	14	15	10	16
Total profit (loss) for period	-25.9%	21	28	39	35	31	41
Other comp. income net of taxes	-266.1%	-0.03	1.62	0.82	-1.58	2.05	-0.25
Total Comprehensive Income	-31%	21	30	40	33	33	40
Earnings Per Share, Basic	-25.3%	24.88	32.96	46.41	40.79	36.44	47.84
Earnings Per Share, Diluted	-	24.88	0	46.41	40.79	36.44	47.84

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	-25.3%	63	84	82	79	67	70
Other Income	710.7%	7.81	1.84	1.23	4.14	0.99	4.36
Total Income	-17.6%	71	86	83	83	68	75
Cost of Materials	6.7%	17	16	16	14	13	14
Purchases of stock-in-trade	87.6%	4.79	3.02	5.09	6.41	5.96	6.02
Employee Expense	0%	16	16	16	16	16	16
Finance costs	-198.4%	-3.81	5.89	5.01	6.94	2.19	8.07
Depreciation and Amortization	2.8%	4.29	4.2	4.13	3.74	3.75	4.28
Other expenses	-8.7%	22	24	25	26	21	21
Total Expenses	-21.6%	59	75	74	74	63	70
Profit Before exceptional items and Tax	10%	12	11	9.73	9.39	5.2	5.21
Total profit before tax	10%	12	11	9.73	9.39	5.2	5.21
Current tax	-72.7%	1.65	3.38	3.08	3.92	1.74	2.67
Deferred tax	23.3%	0.31	0.1	0.03	-0.45	0.66	0.05
Total tax	-61.3%	1.96	3.48	3.11	3.47	2.39	2.72
Total profit (loss) for period	35.3%	11	8.39	7.49	6.39	4.02	4.04
Other comp. income net of taxes	-73.4%	-0.37	0.21	0.39	1.15	-0.23	-0.57
Total Comprehensive Income	31.6%	11	8.6	7.88	7.55	3.79	3.47
Earnings Per Share, Basic	40.1%	13.41	9.86	8.8	7.52	4.73	4.75
Earnings Per Share, Diluted	40.1%	13.41	9.86	8.8	7.52	4.73	4.75

Valuation
Market Cap	1.56 kCr
Price/Earnings (Trailing)	46.43
Price/Sales (Trailing)	4.83
EV/EBITDA	21.48
Price/Free Cashflow	89.47
MarketCap/EBT	36.86

Fundamentals
Revenue (TTM)	323.45 Cr
Rev. Growth (Yr)	4.49%
Rev. Growth (Qtr)	-16.96%
Earnings (TTM)	33.68 Cr
Earnings Growth (Yr)	183.78%
Earnings Growth (Qtr)	35.96%

Profitability
Operating Margin	13.12%
EBT Margin	13.12%
Return on Equity	10.72%
Return on Assets	5.03%
Free Cashflow Yield	1.12%

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
BAYERCROP	Bayer CropSciencePesticides & Agrochemicals	23.1 kCr	5.08 kCr	-2.23%	-12.34%	34.67	4.54	-3.78%	-15.04%
GODREJAGRO	Godrej AgrovetAnimal Feed	14.83 kCr	9.42 kCr	+2.31%	+40.54%	36.81	1.57	-1.47%	+26.87%
AVANTIFEED	Avanti FeedsAnimal Feed	12.13 kCr	5.66 kCr	-2.54%	+68.33%	23.67	2.14	+6.80%	+33.92%
SEQUENT	Sequent ScientificPharmaceuticals	3.66 kCr	1.53 kCr	+11.64%	+15.59%	157.88	2.39	+10.41%	+118.77%

Investor Care
Dividend Yield	0.98%
Dividend/Share (TTM)	14
Shares Dilution (1Y)	0.00%
Diluted EPS (TTM)	39.59

HESTERBIO - Hester Biosciences Ltd Share Price

What does Hester Biosciences Ltd do?

Sector Comparison: HESTERBIO vs Pharmaceuticals & Biotechnology

Comparative Metrics

Performance Comparison

Revenue Breakdown

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Balance Sheet for Hester Biosciences

Cash Flow for Hester Biosciences

Income Statement for Hester Biosciences

Valuation

Fundamentals

Profitability

Is Hester Biosciences Better than it's peers?

Investor Care

Financial Health

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)